Patents Assigned to Centers For Disease Control and Prevention
-
Patent number: 8435794Abstract: A process for testing a composition as containing an artemisinin derivative is provided that includes contacting the composition with a reagent made up of a hydrogen bonding polar organic solvent and an acid having a pK value of less than 3.8 at 25° Celsius and capable of acid catalyzing a decomposition reaction of the artemisinin derivative so as to provide a reaction mixture. The reaction mixture is allowed sufficient time at a reaction temperature for the artemisinin derivative to decompose to yield a colored decomposition product discerned by a normal unaided human eye. A kit for testing a composition for an artemisinin derivative according to the process is provided together with instructions for contacting the solvent and the acid with the composition to decompose the artemisinin derivative to yield the colored decomposition.Type: GrantFiled: November 5, 2008Date of Patent: May 7, 2013Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventor: Michael D. Green
-
Patent number: 8431134Abstract: Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which includes the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present on the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administered. Compositions containing isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present of the surface of a pathogen of interest are also disclosed. In some examples, the compositions also include isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a.Type: GrantFiled: July 31, 2009Date of Patent: April 30, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Edwin W. Ades, Gowrisankar Rajam, Sandra Steiner, George M. Carlone, Nikkoj Melnick, Jacquelyn S. Sampson, Joseph E. Martinez, Julie M. Skinner
-
Patent number: 8433523Abstract: Clinical samples can be analyzed using microparticles to determine the serodiagnosis of a viral infection from two candidate viral infections of the same viral group. Serodiagnosis can be determined via a pooled population of subsets of microparticles, with the particles in the pooled population having a bound viral group-reactive antibody and the particles in each subset having at least one characteristic classification parameter that distinguishes between subsets. Viral antigens of antibodies of interest in the same viral-class as the viral group-reactive antibody can be bound to the viral group-reactive antibody on the microparticles, and subsequently exposed to a clinical sample. Binding and labeling can be used. Automated analysis of data from multiplexed flow analysis can determine the presence or absence of antibodies of interest in the sample, thereby diagnosing for two candidate viral infections in a single assay.Type: GrantFiled: April 25, 2011Date of Patent: April 30, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Center for Disease Control and PreventionInventor: Alison Jane Basile
-
Patent number: 8426574Abstract: Provided herein is a novel human astrovirus, its nucleic acid sequence, as well as methods to detect and diagnose the presence of the astrovirus.Type: GrantFiled: May 28, 2010Date of Patent: April 23, 2013Assignees: Washington University, The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: David Wang, Herbert Whiting Virgin, IV, Guoyan Zhao, Stacy Finkbeiner, Jan Vinje, Yan Li, Suxiang Tong
-
Publication number: 20130095489Abstract: Compositions and process are provided for the rapid and specific detection of drug resistant forms of Mycobacterium tuberculosis based on real time PCR and high resolution melt analysis. The compositions and processes are useful for the detection of mutations within the Rifampicin Resistance Determinant Region (RRDR) of rpoB for the detection of rifampicin (RIF) and within specific regions of katG and the inhA promoter for the detection of isoniazid (INH) resistance. The invention also is capable of rapidly discriminating Mycobacterium tuberculosis complex (MTBC) strains from Nontuberculous Mycobacteria (NTM) strains.Type: ApplicationFiled: May 4, 2011Publication date: April 18, 2013Applicant: CENTERS FOR DISEASE CONTROL AND PREVENTIONInventors: James Posey, Jonas Winchell, Kelley Cowart, Melissa Ramirez
-
Patent number: 8420607Abstract: The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies.Type: GrantFiled: December 24, 2008Date of Patent: April 16, 2013Assignees: University of Georgia Research Foundation, Inc., The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Russell W. Carlson, Geert-Jan Boons, Conrad Quinn, Mahalakshmi Vasan, Margreet A. Wolfert, Biswa Choudhury, Elmar Kannenberg, Christine Leoff, Alok Mehta, Elke Saile, Jana Rauvolfova, Patricia Wilkins, Alex J. Harvey
-
Patent number: 8420107Abstract: This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies.Type: GrantFiled: March 22, 2012Date of Patent: April 16, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Bernard W. Beall, George M. Carlone, Jacquelyn S. Sampson, Edwin W. Ades
-
Publication number: 20130089877Abstract: The present inventors screened peptides having a specific sequence specifically binding to amyloid-beta antibody and accordingly confirmed that A?22(pE)-42 peptide showed higher reactivity to amyloid-beta antibody in serum of Alzheimer's disease patients. Therefore, the said A?22(pE)-42 peptide can be used as an active ingredient for the kit for diagnosing dementia and thus it can be said that the peptide can be effectively used for the diagnosis of dementia whose early diagnosis is hardly possible.Type: ApplicationFiled: October 5, 2012Publication date: April 11, 2013Applicant: KOREA CENTER FOR DISEASE CONTROL AND PREVENTIONInventor: Korea Center For Disease Control And Prevention
-
Publication number: 20130089536Abstract: The present invention relates to a GCP II (glutamate carboxypeptidase II) mutant (K699S) having the activity of inhibiting glutamate production and the activity of cleavaging ?-amyloid, and to a pharmaceutical composition for the prevention and treatment of a disease selected from the group consisting of amyloidosis, Alzheimer's disease, Down syndrome accompanying Alzheimer's disease, stroke, dementia, Huntington's disease, Pick's disease, and Creutzfeldt-Jakob disease comprising the GCP II mutant (K699S) as an active ingredient. The GCP II (glutamate carboxypeptidase II) mutant (K699S) demonstrates not only excellent A? cleavage activity compared with the wild type GCP II but also excellent activity of inhibiting glutamate production, unlike the wild type GCP II, so that the mutant has been confirmed to have higher effect and stability than the wild type, suggesting that the GCP II mutant can be effectively used for the prevention or treatment of neurodegenerative diseases.Type: ApplicationFiled: October 8, 2012Publication date: April 11, 2013Applicant: KOREA CENTER FOR DISEASE CONTROL AND PREVENTIONInventor: Korea Center For Disease Control and Prevention
-
Patent number: 8394600Abstract: Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for a membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis.Type: GrantFiled: March 23, 2012Date of Patent: March 12, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventor: Arnold R. Castro
-
Patent number: 8389229Abstract: Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis.Type: GrantFiled: March 15, 2012Date of Patent: March 5, 2013Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Arnold R. Castro, Robert W. George
-
Publication number: 20130039926Abstract: Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.Type: ApplicationFiled: July 19, 2012Publication date: February 14, 2013Applicants: Center for Disease Control and Prevention, University of MassachusettsInventors: William D. Thomas, JR., Donna M. Ambrosino, Robert Mandell, Susan Sloan, Gregory J. Babcock, Charles Rupprecht
-
Patent number: 8357488Abstract: Methods of detecting Streptococcus pneumoniae (S. pneumoniae), are disclosed. A sample suspected of containing a nucleic acid of S. pneumoniae is screened for the presence or absence of that nucleic acid. The presence of the S. pneumoniae nucleic acid indicates the presence of S. pneumoniae. Determining whether the S. pneumoniae nucleic acid is present in the sample can be accomplished by detecting hybridization between a S. pneumoniae probe, such as a S. pneumoniae lytA probe, a S. pneumoniae psaA probe, or a S. pneumoniae ply probe. Probes and primers for the detection of S. pneumoniae are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.Type: GrantFiled: May 16, 2008Date of Patent: January 22, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Lesley McGee, Maria Lucia Tondella, Maria da Gloria Siqueira Carvalho
-
Patent number: 8357525Abstract: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.Type: GrantFiled: September 4, 2008Date of Patent: January 22, 2013Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Baoming Jiang, Roger I. Glass, Jean-Francois Saluzzo
-
Patent number: 8354115Abstract: The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.Type: GrantFiled: April 4, 2008Date of Patent: January 15, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Ralph A. Tripp, Larry J. Anderson, Michael P. Brown
-
Publication number: 20120329041Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.Type: ApplicationFiled: September 4, 2012Publication date: December 27, 2012Applicant: Centers for Disease Control and PreventionInventors: Jeffrey A. Johnson, Walid M. Heneine
-
Patent number: 8328729Abstract: The present disclosure concerns embodiments of an acoustic plethysmograph for measuring pulmonary function of an animal, such as a mouse. The plethysmograph in exemplary embodiments can measure thoracic tidal volume of an unrestrained animal. The plethysmograph in exemplary embodiments acoustically excites the chamber containing the animal and detects changes in the acoustic pressure in the chamber, which correlate to the thoracic tidal volume of the animal. Unlike the conventional whole-body plethysmograph, this acoustic plethysmograph provides a direct measure of thoracic tidal volume. The plethysmograph also can be configured to measure chamber flow (the flow of air into and out of the chamber). Specific airway resistance of the animal can then be determined from the thoracic tidal volume and plethysmograph flow measurements.Type: GrantFiled: July 7, 2008Date of Patent: December 11, 2012Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Jeffrey S. Reynolds, David G. Frazer
-
Publication number: 20120308597Abstract: Regions of Bacillus anthracis protective antigen are provided representing epitopes recognized by antibodies in subjects that have acquired immunity to Bacillus anthracis infection. The recognition of these epitopes correlates with autoimmunity in a subject. Also provided are vaccines that include at least one of these epitopes that when administered to a subject provide improved acquired immunity.Type: ApplicationFiled: February 10, 2011Publication date: December 6, 2012Applicant: Centers for Disease Control and PreventionInventors: Vera A. Semenova, Conrad P. Quinn, Jan Pohl, Pavel Svoboda
-
Patent number: 8318428Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.Type: GrantFiled: January 24, 2012Date of Patent: November 27, 2012Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Jeffrey A. Johnson, Walid Heneine
-
Patent number: RE43914Abstract: An antigen composition and method for the detection of antibodies to Treponema pallidum and the diagnosis of syphilis are described. The antigen composition contains synthetic cardiolipin and synthetic lecithin. The antigen composition may additionally contain cholesterol and an alcohol. The antigen composition is useful as an immunoreagent in immunoassays for the detection of antibodies associated with T. pallidum infection. The methods are sensitive and specific for T. pallidum infection.Type: GrantFiled: June 8, 2000Date of Patent: January 8, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventor: Arnold R. Castro